AFP DEPARTMENT COLLECTION
Diagnostic Tests: What Physicians Need to Know
The Diagnostic Tests department uses a structured approach to provide concise reviews of new diagnostic tests, including discussions of test accuracy, benefits, harms, cost, and clinical bottom line.
Sep 1, 2020 Issue
Placental Alpha Macroglobulin-1 (PartoSure) Immunoassay to Assess the Risk of Spontaneous Preterm Birth
Placental alpha macroglobulin-1 (PartoSure-TM) immunoassay to assess the risk of spontaneous preterm birth.
Jul 1, 2020 Issue
PAULA’s Test for Lung Cancer Screening
Because of insufficient evidence of benefit, no recommendations can be made regarding PAULA's test. Prospective cohort studies of a screening population and randomized controlled trials comparing cancer mortality outcomes using PAULA's test vs. low-dose CT and no screening are needed before the test can be recommended as a screening option.
May 1, 2020 Issue
IBSchek for Irritable Bowel Syndrome
IBSchek is a blood test marketed to assist in the diagnosis of irritable bowel syndrome with predominant diarrhea (IBS-D) or with mixed bowel habits (IBS-M) in adults.
Mar 1, 2020 Issue
IDx-DR for Diabetic Retinopathy Screening
IDx-DR is a reliable screening tool used to diagnose diabetic retinopathy in the primary care office and may reduce barriers to screening and improve gaps in eye care for those with diabetes.
Jan 1, 2020 Issue
PLAC Test for Lp-PLA2 Activity to Predict Coronary Heart Disease
The PLAC test is a blood test used to measure serum activity of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme that breaks down oxidized low-density lipoprotein in the vascular wall.
Nov 1, 2019 Issue
Allopurinol Hypersensitivity Assay HLA-B*58:01 Genotyping
The allopurinol hypersensitivity assay, or HLA-B*58:01 test, is a blood test to detect the presence of a human leukocyte antigen B (HLA-B) genetic variant that increases the risk of life-threatening, severe cutaneous adverse reactions in patients taking allopurinol.
Sep 1, 2019 Issue
Prolaris Test for Prostate Cancer Risk Assessment
The Prolaris test improves the accuracy of prognosis for patients with prostate cancer, especially those with low- or intermediate-grade disease who may be deciding between interventional and noninterventional treatment approaches.
Jul 1, 2019 Issue
mSEPT9 (Epi proColon) Blood Test for Colorectal Cancer Screening
Epi proColon is a blood test used for the detection of the methylated septin 9 (mSEPT9) gene. It is approved by the U.S. Food and Drug Administration for colorectal cancer screening in people at average risk who have declined first-line screening tests.